U.S. Ebola Patient Treated with Experimental Antiviral Drug

According to an AP article, Chimerix Inc. is providing its experimental antiviral drug, brincidofovir, to treat Thomas Eric Duncan, the Dallas patient who has Ebola. The drug was authorized by the Food and Drug Administration.

Brincidofovir is an antiviral drug being tested against common viruses, including one that infects patients undergoing bone marrow transplants. Laboratory tests suggested it may also work against Ebola, the article said.

The company said it is working with the FDA to finalize plans for an Ebola study of brincidofovir. The company has no other products on the market or in testing. Read the full AP article